SCHEMBL4047572

SCHEMBL4047572

COc1ccc(Nc2[nH]nc3c2Cc2c(OC)cccc2-3)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.46
PDGFRB P09619 2/20 0.44
STK10 O94804 1/20 0.43
SLK Q9H2G2 1/20 0.43
KMT2A Q03164 2/20 0.41
MAPT P10636 3/20 0.40
HIF1A Q16665 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
GAA P10253 2/20 0.40
MEN1 O00255 1/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
TTK P33981 1/20 0.39
ACHE P22303 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ALDH1A1 P00352 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4040925 0.91 KMT2A (0.46) TP53PDGFRBSTK10SLKKMT2A
SCHEMBL13145999 0.91 PDGFRB (0.44) TP53PDGFRBKMT2AMAPTHIF1A
SCHEMBL4044383 0.85 PDGFRB (0.52) PDGFRBSTK10SLKKMT2AMAPT
SCHEMBL4045624 0.84 PDGFRB (0.47) TP53PDGFRBKMT2AMAPTHIF1A
SCHEMBL4042479 0.83 CHEK1 (0.51) PDGFRB
SCHEMBL4044173 0.83 KMT2A (0.41) TP53PDGFRBKMT2AMAPTSMN1; SMN2
SCHEMBL4043886 0.80 PDGFRB (0.63) PDGFRBSTK10SLKHIF1AACHE
SCHEMBL4366459 0.78 PDGFRB (0.52) PDGFRBKMT2AHIF1ANPC1MEN1
SCHEMBL4044548 0.78 PDGFRB (0.43) TP53PDGFRBSTK10SLKMAPT
SCHEMBL4038939 0.78 PDGFRB (0.52) TP53PDGFRBSTK10SLKKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795440-B2 N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders JANSSEN PHARMACEUTICA NV (BE) 2010-09-14 US disclosed
US-7795440-B2 N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders JANSSEN PHARMACEUTICA NV (BE) 2010-09-14 US disclosed
EP-1506175-B1 N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2009-04-01 EP disclosed
US-20070142305-A1 N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders HO CHIH Y 2007-06-21 US disclosed
US-20070142305-A1 N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders HO CHIH Y 2007-06-21 US disclosed
US-7196110-B2 N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders JANSSEN PHAMACEUTICA N.V. (BE) 2007-03-27 US disclosed
US-7196110-B2 N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders JANSSEN PHAMACEUTICA N.V. (BE) 2007-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142305-A1 N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders PDGFRA, PDGFRB, PDGFA TP53 109/4885PDGFRB 2/4885STK10 1239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.